Core Insights - The strategic cooperation agreement between Guangzhou Pharmaceutical Group and JD Health aims to leverage digital innovation to enhance supply chain collaboration, market operations, and user services, ultimately providing consumers with more efficient health products and services [1][2] Group 1: Partnership Objectives - The partnership focuses on product innovation, channel co-construction, and service integration to boost health consumption confidence and explore joint investment and resource integration for industry upgrades [1][2] - Both companies aim to create a multi-layered, integrated cooperation system to optimize resource allocation and value release [1] Group 2: Historical Context and Growth - Since the deep cooperation began in 2017, the partnership has maintained a high compound growth rate of over 20% in business operations over the past three years, laying a solid foundation for this strategic upgrade [2] - The companies plan to establish a normalized, multi-level collaborative mechanism to enhance decision-making and execution [2] Group 3: Future Collaboration Focus - Future efforts will concentrate on precise procurement, intelligent inventory management, and automated replenishment to build an agile and efficient supply chain [3] - JD Health's big data analytics will enable Guangzhou Pharmaceutical's products to reach consumers more effectively, while leveraging JD Health's extensive logistics network to optimize warehousing, transportation, and delivery [3] Group 4: Market and User Engagement - The partnership will utilize JD Health's vast user resources and data capabilities to gain insights into user needs, enhancing service precision and personalization [3] - New products from Guangzhou Pharmaceutical will be prioritized for launch on JD Health's platform, with joint efforts in precision marketing to facilitate market entry [3] Group 5: Social Responsibility and Industry Transformation - The collaboration will also focus on corporate social responsibility, exploring mechanisms for the recycling of expired medications through existing platforms [3] - This partnership represents a significant step towards the integration of products, services, and platforms in the pharmaceutical and health industry [3]

Core Insights - Hanwang and JD Health have signed a cooperation agreement to launch the "Precise Measurement · Nurse at Home" initiative, providing home guidance and standardized measurement processes for users of Hanwang's K-type electronic blood pressure monitors in 20 cities across China [1] Group 1: Service Offering - The "Nurse at Home" service includes professional blood pressure measurement demonstrations, education on the K-type method, comparisons with traditional mercury sphygmomanometers, and personalized reminders for users [1] - The service aims to help users achieve accurate blood pressure measurements at home, closely resembling the experience in hospitals [1] Group 2: Target Market - The initial rollout of the service will cover key cities such as Shanghai, Tianjin, Chongqing, Wuhan, and Chengdu, and is available for users who have purchased the Hanwang K-type electronic blood pressure monitor [1] Group 3: Product Features - The newly launched Hanwang KSY3610 electronic blood pressure monitor not only measures blood pressure but also provides five key indicators: blood pressure, heart rate, pulse pressure, atrial fibrillation screening results, and irregular pulse alerts [1] Group 4: Industry Context - Hanwang has previously promoted the "Mercury-Free Action" to replace mercury sphygmomanometers in medical institutions, and the new "Nurse at Home" service complements this initiative by extending support to individual households [1]

京东健康CEO曹冬表示，广药集团是京东健康最重要的战略伙伴之一，希望未来能够更好地将广药的优 质产品与京东健康的数字能力、服务场景紧密结合，挖掘新的增长机会，共同为更多用户提供优质的健 康服务。 据悉，自2017年开启深度合作以来，广药集团与京东健康始终秉持互信共赢的理念，合作成果丰硕，过 去三年双方合作业务更是保持了20%以上的高复合增长，为此次战略升级奠定了坚实基础。 就合作项目的落地，广药集团党委副书记、副董事长、总经理陈杰辉表示，接下来双方构建常态化全层 级协同机制，决策层引领、执行层推进、业务层联动；深化优势互补，聚焦大品种拓展等领域突破；拓 展创新边界，共探出海等新场景合作，力争今年合作业务大幅增长，明年向更高目标迈进。 本报讯(记者王镜茹)10月21日，广州医药集团有限公司(以下简称"广药集团")与京东健康在广州签署战 略合作协议。 根据合作协议，双方将以数智创新为核心引擎，整合产品、渠道、技术和服务资源，围绕供应链协同、 市场运营、用户服务等维度，构建多层次、一体化的合作体系，推动资源高效整合与价值释放，为消费 者提供更高效、便捷的健康产品与服务体验。 广药集团党委书记、董事长李小军表示，此次 ...

Core Viewpoint - The strategic cooperation agreement between Guangzhou Pharmaceutical Group and JD Health aims to leverage digital innovation to enhance resource integration and value release in the pharmaceutical and healthcare industry [1][2]. Group 1: Strategic Cooperation - The agreement focuses on integrating products, channels, technology, and service resources to build a multi-layered, integrated cooperation system [1]. - Both companies aim to deepen collaboration in product innovation, channel development, and service integration, while exploring joint investment and resource integration for industry upgrades [1][2]. Group 2: Business Growth and Collaboration - Since their deep cooperation began in 2017, the partnership has achieved over 20% compound annual growth rate in business collaboration over the past three years [1]. - Future efforts will include establishing a regular collaboration mechanism across all levels, focusing on major product expansion and exploring new cooperation scenarios such as international markets [2]. Group 3: Supply Chain and User Services - The partnership will enhance supply chain efficiency through precise procurement, smart inventory management, and automated replenishment, utilizing JD Health's extensive delivery network [2]. - Guangzhou Pharmaceutical Group will leverage JD Health's user data to improve service precision and personalization, with new products launching first on JD Health's platform [2]. Group 4: Corporate Social Responsibility - Both companies will collaborate on a drug recycling initiative, combining Guangzhou Pharmaceutical Group's existing program with JD Health's public welfare platform [2].

临近世界男性健康日，京东健康将于10月20日－11月10日开展一系列活动，通过名医义诊、名医科普、 医患故事讲述等，增进大众对男性健康的了解。10月27日，京东健康还将主办"第一届男性健康行业峰 会"，邀请医学专家解析男科诊疗现状、探讨互联网诊疗规范、药品品质需求等话题，共同守护男性健 康。 京东健康专科医疗业务负责人表示，京东互联网男科中心期待携手行业协会及权威专家进行临床规范制 定、疑难病例会诊、专业人才培养及科学研究、健康科普内容创作，共同推动互联网男科诊疗高质量发 展，为患者提供更便捷、更专业、更安全的医疗服务。 （编辑 郭之宸） 与会专家指出，当前互联网医院男科建设还存在营销推广不规范、治疗收费不透明、隐私保障不到位等 现象，男科规范性亟待提高。针对互联网男科建设痛点，京东互联网医院着力构建专业医疗团队与服务 矩阵，提升男科规范化水平。 2024年，京东互联网医院全面发力男科中心建设，与中国非公立医疗机构协会男科专业委员会达成战略 合作，共同打造全国首家"互联网医院男科规范诊疗示范基地"。截至目前，男科中心汇聚超1500名注册 医师，其中三甲医院医生超1000名。依托京东健康医药供应链优势，中心覆盖 ...

Core Insights - The article discusses the seasonal increase in blood pressure among hypertension patients during autumn and winter, emphasizing the importance of accurate blood pressure measurement [1][3] - A collaboration between Hanwang and JD Health has been established to launch the "Precise Measurement: Nurse at Home" initiative, aimed at providing home guidance for blood pressure measurement in 20 cities across China [1][3] Group 1 - The "Precise Measurement: Nurse at Home" service includes four main components: demonstration of professional blood pressure measurement standards, explanation of the Korotkoff sound principle, comparison with traditional mercury sphygmomanometers, and personalized reminders for users [3] - The new Hanwang Korotkoff electronic blood pressure monitor KSY3610 provides five key indicators: blood pressure, heart rate, pulse pressure, atrial fibrillation screening, and irregular pulse detection, with alerts for potential health issues [3] - Measurement data from the KSY3610 can be transmitted in real-time to the Hanwang Health APP, allowing users and healthcare providers to track trends and generate reports for better health management [3] Group 2 - The service is initially available in major cities such as Shanghai, Tianjin, Chongqing, Wuhan, and Chengdu, targeting existing users of the Hanwang Korotkoff electronic blood pressure monitor [3]

Group 1 - The core viewpoint of the article is the strategic partnership between JD Health and Guangzhou Pharmaceutical Group, aimed at enhancing supply chain efficiency through integrated solutions [1] Group 2 - JD Health will provide an all-channel sales and supply chain integration solution to Guangzhou Pharmaceutical Group [1] - The collaboration will focus on precise procurement, intelligent inventory management, and automated replenishment [1] - The goal is to build a more agile and efficient supply chain system [1]

每经AI快讯，京东健康(06618.HK)早盘涨超5%，截至发稿，涨3.95%，报63.15港元，成交额8099.76万 港元。 ...

Core Viewpoint - JD Health's stock price has shown significant upward movement, with a notable increase of over 5% in early trading, reflecting positive market sentiment regarding its future performance [1] Group 1: Financial Performance Expectations - Bank of America Securities has released a report indicating that JD Health's performance in the first half of 2025 is expected to significantly exceed market expectations, with continued strong growth anticipated in the second half [1] - The firm has revised its forecasts for JD Health's third quarter, expecting the company to maintain rapid revenue growth momentum seen in the first half [1] - For the fourth quarter, Bank of America remains conservative with its predictions, awaiting more visibility post the Double Eleven shopping festival [1] Group 2: Margin and Growth Projections - Bank of America anticipates that JD Health's gross margin will expand year-on-year in the second half of the year [1] - Macquarie forecasts that JD Health will continue to experience strong growth in the second half, driven by the direct launch of new drugs and increased advertising spending from merchants [1] - Macquarie expects that the enhanced contribution from drug sales will positively impact overall gross margin, projecting a year-on-year expansion of 1.5 percentage points to 23.7% in the second half [1]

Core Viewpoint - JD Health's stock price has shown significant upward movement, with a notable increase of over 5% in early trading, reflecting positive market sentiment driven by strong performance expectations for the second half of 2025 [1] Group 1: Performance Expectations - Bank of America has released a report indicating that JD Health's performance in the first half of 2025 will significantly exceed expectations, with continued strong performance anticipated in the second half [1] - The bank has revised its forecasts for JD Health's third quarter, expecting the company to maintain rapid revenue growth momentum seen in the first half [1] - For the fourth quarter, Bank of America remains conservative with its predictions, awaiting more visibility post the Double Eleven shopping festival [1] Group 2: Margin and Growth Projections - Macquarie forecasts that JD Health will continue to experience strong growth in the second half, benefiting from the direct launch of new drugs and increased advertising spending from merchants [1] - The firm anticipates that the enhanced contribution from drug sales will positively impact overall gross margins, projecting a year-on-year expansion of 1.5 percentage points to 23.7% in the second half [1] - Macquarie believes that the growth rates across product categories (drugs > supplements > devices) will remain stable, and the company's supply chain capabilities along with faster-growing market revenues will offset any potential margin pressures [1]